HOTH Key Statistics, Chart & Performance
The current stock price of HOTH is 1.2 USD. In the past month the price decreased by -6.25%. In the past year, price increased by 43.44%.
HOTH Latest News, Press Relases and Analysis
HOTH Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 45.94 | 955.13B | ||
| JNJ | JOHNSON & JOHNSON | 19.45 | 486.51B | ||
| MRK | MERCK & CO. INC. | 11.32 | 247.51B | ||
| PFE | PFIZER INC | 8.13 | 148.00B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.95 | 106.16B | ||
| ZTS | ZOETIS INC | 18.71 | 52.29B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.67 | 22.93B | ||
| VTRS | VIATRIS INC | 4.69 | 12.59B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.81 | 10.88B | ||
| CORT | CORCEPT THERAPEUTICS INC | 97.85 | 9.06B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.52B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.23B |
Related stock screener links
About HOTH
Company Profile
Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. The company is headquartered in New York City, New York and currently employs 2 full-time employees. The company went IPO on 2019-02-15. The firm is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT), and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The firm also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004), and a treatment for obesity, and obesity-related diseases and conditions (HT-VA).
Company Info
HOTH THERAPEUTICS INC
1177 Avenue Of The Americas, 5Th Floor Suite 5066
New York City NEW YORK 10020 US
CEO: Robb Knie
Employees: 2
Phone: 16467562997
HOTH THERAPEUTICS INC / HOTH FAQ
What does HOTH do?
Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. The company is headquartered in New York City, New York and currently employs 2 full-time employees. The company went IPO on 2019-02-15. The firm is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT), and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The firm also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004), and a treatment for obesity, and obesity-related diseases and conditions (HT-VA).
Can you provide the latest stock price for HOTH THERAPEUTICS INC?
The current stock price of HOTH is 1.2 USD. The price increased by 0.84% in the last trading session.
What is the dividend status of HOTH THERAPEUTICS INC?
HOTH does not pay a dividend.
How is the ChartMill rating for HOTH THERAPEUTICS INC?
HOTH has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the market capitalization of HOTH stock?
HOTH THERAPEUTICS INC (HOTH) has a market capitalization of 18.61M USD. This makes HOTH a Nano Cap stock.
What is the next earnings date for HOTH stock?
HOTH THERAPEUTICS INC (HOTH) will report earnings on 2026-03-26, after the market close.
What is the Short Interest ratio of HOTH THERAPEUTICS INC (HOTH) stock?
The outstanding short interest for HOTH THERAPEUTICS INC (HOTH) is 3.52% of its float.
HOTH Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to HOTH. When comparing the yearly performance of all stocks, HOTH is one of the better performing stocks in the market, outperforming 82.53% of all stocks.
HOTH Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to HOTH. No worries on liquidiy or solvency for HOTH as it has an excellent financial health rating, but there are worries on the profitability.
HOTH Financial Highlights
Over the last trailing twelve months HOTH reported a non-GAAP Earnings per Share(EPS) of -1.06. The EPS increased by 20.3% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -131.58% | ||
| ROE | -147.77% | ||
| Debt/Equity | 0 |
HOTH Forecast & Estimates
7 analysts have analysed HOTH and the average price target is 4.59 USD. This implies a price increase of 282.5% is expected in the next year compared to the current price of 1.2.